Publications by authors named "Elfi B Conemans"
Context: Cyproterone acetate (CPA) is a competitive inhibitor of the androgen receptor and exerts negative hypothalamic feedback. It is often used in combination with estrogens in trans women to achieve feminization. However, CPA has been associated with side effects such as changes in liver enzyme concentrations and increases in prolactin concentrations.
View Article and Find Full Text PDFContext: Erythrocytosis is a known side effect of testosterone therapy that can increase the risk of thromboembolic events.
Objectives: To study the prevalence and determinants in the development of erythrocytosis in trans men using testosterone.
Methods: A 20-year follow-up study in adult trans men who started testosterone therapy and had monitoring of hematocrit at our center (n = 1073).
Objective: Transgender individuals sometimes report a lack of physical change during hormone treatment, such as alterations in muscle tone or fat distribution. Identifying characteristics of this subgroup could be a step toward individualizing hormone therapy in transgender individuals. Therefore, we study the variation of changes in body composition and characteristics associated with a lack of change.
View Article and Find Full Text PDFAn amendment to this paper has been published and can be accessed via a link at the top of the paper.
View Article and Find Full Text PDFMost pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are therefore considered 'non-functional'. As clinical behaviors vary widely and distant metastases are eventually lethal, biological classifications might guide treatment. Using enhancer maps to infer gene regulatory programs, we find that non-functional PNETs fall into two major subtypes, with epigenomes and transcriptomes that partially resemble islet α- and β-cells.
View Article and Find Full Text PDFIntroduction: Although many studies on the short- and long-term effects of hormonal treatment (HT) in trans people focus on objective changes such as body composition or bone density, few studies have evaluated self-reported effects of HT.
Aim: To evaluate self-reported symptoms during the first year of HT in trans people.
Methods: This study is part of the European Network for the Investigation of Gender Incongruence, a multicenter prospective cohort study.
Article Synopsis
- The study investigates the relationship between the World Health Organization (WHO) grading of pancreatic neuroendocrine tumors (PanNETs) and the risk of liver metastases in patients with Multiple Endocrine Neoplasia Type 1 (MEN1).
- Data were collected from a national database in the Netherlands, analyzing a cohort of 69 MEN1 patients who underwent pancreatic surgery, focusing on tumor size and mitotic count as indicators of prognosis.
- The findings reveal that higher mitotic counts in larger PanNETs correlate with an increased likelihood of liver metastases, highlighting the importance of mitotic evaluation for assessing prognosis in these patients.
Objective: Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Overall survival (OS) and prognostic factors for patients with liver metastases from DP-NETs are not known.
Methods: This was a cohort study using the Dutch National MEN1 database, which includes >90% of the Dutch MEN1 population treated between 1990 and 2014.
Objective: Currently, little is known about the prevalence of thyroid tumors in multiple endocrine neoplasia type 1 (MEN1) patients and it is unclear whether tumorigenesis of these thyroid tumors is MEN1-related. The aim of the study was to assess the prevalence of thyroid incidentalomas in MEN1 patients compared with nonMEN1 patients and to verify whether thyroid tumorigenesis is MEN1-related.
Design: A cross-sectional study.